United States ── Legal commentary

27 records since 1990, judged by Jev for relevance, jurisdiction, type and importance.

2026 3

• Legal commentary2026-07-30ICLG
  Evolving Regulatory Landscape for Healthcare Communications
• Legal commentary2026-04-01eYLS (Yale Law School)
  Prescribing Drug Advertising Regulations in the Age of Social Media
• Legal commentary2026-02-12Milbank Quarterly
  Regulating Direct‐to‐Consumer Prescription Drug Advertising in the United States

2021 1

• Legal commentary2021-03-01PubMed
  The Law and Practice of Off-Label Prescribing and Physician Promotion.

2019 1

• Legal commentary2019-01-01Open Scholarship Institutional Repository (Washington University in St. Louis)
  Addressing the Threshold: Regulating Off-Label Drug Promotion

2017 1

• Legal commentary2017-01-01Seton Hall University eRepository (Seton Hall University)
  “Pharmaceutical Promotion in Interactive Media – How the Statute and Regulations Applied in Digital Era”

2015 3

• Legal commentary2015-11-18Journal of Law and the Biosciences
  Off-label drug promotion and the ephemeral line between marketing and education
• Legal commentary2015-01-01bepress Legal Repository
  What Is "False or Misleading" Off-Label Promotion?
• Legal commentary2015-01-01bepress Legal Repository
  Off-Label Promotion, the First Amendment, and Practically Addressing Antibiotic Resistance

2014 3

• Legal commentary2014-12-31University of North Carolina School of Law Scholarship Repository (University of North Carolina Hospitals)
  Prospects for Regulation of Off-label Promotion in an Era of Expanding Commercial Speech Protection
• Legal commentary2014-01-01Penn Carey Law Legal Scholarship Repository (University of Pennsylvania)
  Off-Label Drug Promotion and the First Amendment
• Legal commentary2014-01-01eYLS (Yale Law School)
  FDA Involvement in Off-label Use: Debate Between Richard Epstein and Ryan Abbott

2012 2

• Legal commentary2012-02-01Biotechnology Law Report
  Pharmaceutical Advertising Often Not in Compliance with FDA Regulations
• Legal commentary2012-01-01Digital USD (University of San Diego)
  The Informational and Institutional Theories of Off-Label Promotion

2011 1

• Legal commentary2011-07-01Defense Counsel Journal
  What Every Pharmaceutical and Medical Device Company Should Know: False Claims Act Cases Based on Off-Label Promotion Promise to Increase with the Healthcare Act and the Bad Ad Program

2009 1

• Legal commentary2009-01-01bepress Legal Repository
  REGULATING DIRECT-TO-CONSUMER ADVERTISING WITH TORT LAW: IS THE LAW FINALLY CATCHING UP WITH THE MARKET?

2007 1

• Legal commentary2007-01-01bepress Legal Repository
  The Difficult Case of Direct-to-Consumer Drug Advertising

2006 1

• Legal commentary2006-01-01Digital Access to Scholarship at Harvard (DASH) (Harvard University)
  Federal Preemption in the Area of Direct-to-Consumer (DTC) Advertising of Prescription Drugs

2005 2

• Legal commentary2005-10-01Defense Counsel Journal
  The Learned Intermediary Doctrine and Beyond: Exploring Direct-to-Consumer Drug Advertising Liability in the New Millennium
• Legal commentary2005-01-01bepress Legal Repository
  False Claims Act Liability for Off-Label Promotion of Pharmaceutical Products

2004 1

• Legal commentary2004-11-01Hospital Pharmacy
  Direct-to-Consumer Advertising of Prescription Drugs: Emerging Legal and Regulatory Issues

2000 3

• Legal commentary2000-08-03Digital Commons-DePaul (DePaul University)
  Direct Advertising of Prescription Drugs: The Duty to Warn and the Learned Intermediary Rule
• Legal commentary2000-01-01Digital Access to Scholarship at Harvard (DASH) (Harvard University)
  Promotion of Unapproved Uses of Approved Drugs and Devices: An Analysis under the First Amendment
• Legal commentary2000-01-01bepress Legal Repository
  Direct-to-Consumer Advertising of Prescription Drugs: After a Decade of Speculation, Courts Consider Another Exception to the Learned Intermediary Rule

1997 2

• Legal commentary1997-08-01Virginia Law Review
  Closing the Channels of Communication: A First Amendment Analysis of the FDA's Policy on Manufacturer Promotion of "Off-Label" Use
• Legal commentary1997-01-01EngagedScholarship @ Cleveland State University (Cleveland State University)
  Blinded by the Hype: Shifting the Burden When Manufacturers Engage in Direct to Consumer Advertising of Prescription Drugs

1993 1

• Legal commentary1993-01-01Scholarship @ Cornell Law (Cornell University)
  Bypassing the Learned Intermediary: Potential Liability for Failure to Warn in Direct-to-Consumer Prescription Drug Advertising